Goodrx Holdings, Inc.

  • Earnings Score
  • Moat Score
  • Safety Score
  • Market Cap $1.64B
  • PE 100
  • Debt $505.00M
  • Cash $448.35M
  • EV $1.69B
  • FCF $182.65M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings$16.39M
EBIT$65.85M
ROE2%
ROA5%
FCF$182.65M
Equity$724.66M
Growth Stability1
PE99.79
PEG-24
PB2.26
P/FCF8.95
P/S2.06
Price/Cash0.27
Debt/Equity0.7
Debt/FCF2.76
Net Margins2%
Gross Margins94%
Op. Margins8%
Earnings CAGR-3%
Sales Growth YoY1%
Sales Growth QoQ2%
Sales CAGR10%
FCF CAGR9%
Equity CAGR-2%
Earnings Stability-0.46
Earnings Growth YoY-126%
Earnings Growth QoQ70%
Earnings CAGR 5Y-4%
Sales CAGR 5Y8%
FCF CAGR 5Y7%
Equity CAGR 5Y-2%
Earnings CAGR 3Y-0%
Sales CAGR 3Y-0%
FCF CAGR 3Y-2%
Equity CAGR 3Y-7%
Market Cap$1.64B
Revenue$792.32M
Assets$1.39B
Total Debt$505.00M
Cash$448.35M
Shares Outstanding385.74M
EV1.69B
Earnings Score6%
Moat Score46%
Safety Score91%
Final Score48%
Working Capital535.35M
Current Ratio5.32
Gross Profit$744.11M
Shares Growth 3y-3%
Equity Growth QoQ4%
Equity Growth YoY-5%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
GoodRx is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It has over 6 million active monthly users. The company's primary focus is the U.S. prescription drug market, where GoodRx has developed a price comparison tool that it aggregates from over 200 billion daily pricing data points, directing consumers toward coupons negotiated between a pharmacy and intermediaries (pharmacy benefit managers ). GoodRx generates revenue by taking a small share of the fees paid by pharmacies to PBMs in exchange for routing consumers to these discount programs, and separately through a subscription-based model (GoodRx Gold), which offers discounted drugs to customers paying a monthly membership fee.

SEC Filings

Direct access to Goodrx Holdings, Inc. (GDRX) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Goodrx Holdings, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Goodrx Holdings, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR -3%
Stability -46%
loading chart...

Goodrx Holdings, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Goodrx Holdings, Inc..

= $3.4B
012345678910TV
fcf$183M$199M$216M$235M$256M$278M$303M$330M$359M$390M$425M$4.2B
DCF$181M$179M$177M$175M$173M$171M$169M$167M$165M$164M$1.6B
Value$3.4B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201812/201912/202012/202112/202212/202312/2024TTM
Net Margins6%11%-53%-3%-4%-1%2%2%
ROA-36%-19%1%0%-2%5%5%
ROE--4%-41%-3%-4%-1%2%2%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201812/201912/202012/202112/202212/202312/2024TTM
Debt over FCF-8.286.213.914.724.782.762.76
Debt over Equity--0.620.970.820.830.860.70.7
Growth Stability-------1

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201812/201912/202012/202112/202212/202312/2024CAGR 5Y
Revenue YoY growth-56%42%35%3%-2%6%8%
Earnings YoY growth-208%-792%-91%30%-73%-285%-4%
Equity YoY growth--6%-165%17%-2%-6%-5%-2%
FCF YoY growth-84%35%57%-18%-4%33%7%